Sucampo Looks To Add Heft With Vtesse Acquisition

In search of a new direction since shelving cobiprostone last summer, Sucampo acquires Cydan-backed startup and Niemann-Pick disease candidate VTS-270, now in a pivotal Phase IIb/III study.

More from Deals

More from Business